Tips For Recruiting, Reporting Trial Subpopulations In FDA Draft Guidance
This article was originally published in The Gray Sheet
FDA instructs device manufacturers and agency staff on its expectations for designing and analyzing trials to reflect outcomes for patient subpopulations, and also provides recruitment tips in a June 20 draft guidance.
You may also be interested in...
A final guidance document from the agency outlines how device sponsors should approach racial, ethnic and age diversity in trial enrollment and data analysis.
The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.
Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.